Antibiotics
Phase
Phase4Study status
RecruitingView details
Sarepta Therapeutics, Inc.
IndicationDuchenne Muscular Dystrophy
Estimated study completion2027-08-31
Cash and cash equivalents · Restricted cash and marketable securities excluded
Cash verified Nov 16, 2026
No verified development in tracked sources.
No upcoming event verified in tracked sources.
34 programs · 38 verified studies
| Company | Drug | Indication | Phase | Study status | Timing | Registry |
|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics, Inc. | Antibiotics | Duchenne Muscular Dystrophy | Phase4 | Recruiting | Estimated study completion2027-08-31 | NCT07542314 |
| SRPT Sarepta Therapeutics, Inc. | AVI-4020 Injection | West Nile Fever | Phase1 | Terminated | Actual study completion2004-11 | NCT00091845 |
| SRPT Sarepta Therapeutics, Inc. | AVI-4020 Injection | West Nile Virus | Phase1 | Completed | Actual study completion2009-06 | NCT00387283 |
| SRPT Sarepta Therapeutics, Inc. | AVI-4065 Injection | Hepatitis C | Phase1 / Phase2 | Terminated | Actual study completion2007-01 | NCT00229749 |
| SRPT Sarepta Therapeutics, Inc. | AVI-4065 Injection | Encephalitis | Phase1 | Completed | Actual study completion2009-06 | NCT00381433 |
| SRPT Sarepta Therapeutics, Inc. | AVI-4126 Injection (RESTEN-NG®) | Neoplasms | Phase1 | Completed | Actual study completion2009-06 | NCT00343148 |
| SRPT Sarepta Therapeutics, Inc. | AVI-4658 (Eteplirsen) | Duchenne Muscular Dystrophy | Phase2 | Completed | Actual study completion2012-06 | NCT01396239 |
| SRPT Sarepta Therapeutics, Inc. | AVI-4658 (Eteplirsen) | Duchenne Muscular Dystrophy (DMD) | Phase2 | Completed | Actual study completion2017-08-16 | NCT01540409 |
| SRPT Sarepta Therapeutics, Inc. | AVI-4658 for Injection | Duchenne Muscular Dystrophy | Phase1 / Phase2 | Completed | Actual study completion2010-12 | NCT00844597 |
| SRPT Sarepta Therapeutics, Inc. | AVI-5126 | Cardiovascular Disease; Coronary Artery Bypass | Phase2 | Terminated | Actual study completion2009-03 | NCT00451256 |
Phase
Phase4Study status
RecruitingSarepta Therapeutics, Inc.
IndicationDuchenne Muscular Dystrophy
Estimated study completion2027-08-31
Phase
Phase1Study status
TerminatedSarepta Therapeutics, Inc.
IndicationWest Nile Fever
Actual study completion2004-11
Phase
Phase1Study status
CompletedSarepta Therapeutics, Inc.
IndicationWest Nile Virus
Actual study completion2009-06
Phase
Phase1 / Phase2Study status
TerminatedSarepta Therapeutics, Inc.
IndicationHepatitis C
Actual study completion2007-01
Phase
Phase1Study status
CompletedSarepta Therapeutics, Inc.
IndicationEncephalitis
Actual study completion2009-06
Phase
Phase1Study status
CompletedSarepta Therapeutics, Inc.
IndicationNeoplasms
Actual study completion2009-06
Phase
Phase2Study status
CompletedSarepta Therapeutics, Inc.
IndicationDuchenne Muscular Dystrophy
Actual study completion2012-06
Phase
Phase2Study status
CompletedSarepta Therapeutics, Inc.
IndicationDuchenne Muscular Dystrophy (DMD)
Actual study completion2017-08-16
Phase
Phase1 / Phase2Study status
CompletedSarepta Therapeutics, Inc.
IndicationDuchenne Muscular Dystrophy
Actual study completion2010-12
Phase
Phase2Study status
TerminatedSarepta Therapeutics, Inc.
IndicationCardiovascular Disease; Coronary Artery Bypass
Actual study completion2009-03
7 unverified sponsor matches remain unlinked.
No verified developments in tracked sources.